Physician profile
Sanjay Shetty
NPI 1821011453
$4,626.66
in general payments reported to CMS, 2019-2025
31 companies · $291 in 2025
The $291 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $625 · 2020: $173 · 2021: $858 · 2022: $1,621 · 2023: $572 · 2024: $487 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,349.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,270.03 | 2019-2025 | Watchman Flx, Watchman Access System, Bodyguardian |
| Novartis Pharmaceuticals Corporation | $1,058.23 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $484.23 | 2019-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $276.30 | 2020-2024 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $257.63 | 2019-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $204.93 | 2019-2024 | Lifevest |
| Pfizer INC. | $127.59 | 2019-2024 | |
| Amgen INC. | $116.73 | 2019-2025 | Repatha |
| Esperion Therapeutics, INC. | $106.62 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $94.22 | 2021-2025 | Verquvo, Zerbaxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.99 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $70.62 | 2019-2022 | |
| Scpharmaceuticals INC. | $50.55 | 2025 | |
| Heartflow, INC. | $46.21 | 2023-2024 | Ffrct |
| Kiniksa Pharmaceuticals, LTD. | $43.85 | 2023 | Arcalyst |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $41.93 | 2021 | |
| Abbott Laboratories | $36.28 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.39 | 2023-2025 | |
| Atricure, INC. | $35.25 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $30.83 | 2024 | Arcalyst |
| Irhythm Technologies, INC. | $27.58 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $25.79 | 2019 | |
| Preventice Services, LLC | $23.53 | 2021 | |
| Genentech USA, INC. | $20.68 | 2025 | Xolair |
| Cvrx, INC. | $19.57 | 2024 | Barostim Neo System |
| Ionis Pharmaceuticals, INC. | $18.52 | 2025 | Tryngolza |
| Kowa Pharmaceuticals America, INC. | $14.57 | 2021 | |
| Novo Nordisk INC | $13.01 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Shetty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.